South San Francisco, CA – According to filings with the U.S. Securities and Exchange Commission, Aligos Therapeutics is raising $125,000,167.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Lawrence Blatt played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Aligos Therapeutics

Aligos Therapeutics is discovering and developing new classes of compounds that interact directly with disease causing molecules. These approaches are targeting viral nucleic acids and their encoded proteins, as well as oncogenes and their resultant proteins. The company is also pursuing novel therapeutic agents aimed at activation of the immune system to resolve diseases that cause significant morbidity and mortality.

To learn more about Aligos Therapeutics, visit http://www.aligos.com/

Contact:
Lawrence Blatt, Chief Executive Officer
800-466-6059
https://www.linkedin.com/in/lawrence-m-blatt-065b2a192/

SOURCE: http://www.intelligence360.io
Copyright (c) 2019 SI360 Inc. All rights reserved